# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

> **NCT07246941** · PHASE1 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 40 (estimated)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** RG6496
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07246941
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-19
- **Primary completion:** 2027-12-11
- **Final completion:** 2029-03-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07246941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07246941, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07246941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*